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ART) is beneficial for short-
term outcomes, the survival,
quality of life, and cost out-
comes were never evaluated.
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results indicate that, accord-
ing to the available data,
PET-ART for non-small cell
lung cancer seems to be cost-
effective compared with
conventional radiation
therapy.gave a 36%probability that PET-ARTimproves health outcomes at reduced costs and a 64%
probability that PET-ART is more effective at slightly higher costs.
Conclusion: On the basis of the available data, individualized PET-ART for NSCLC seems
to be cost-effective compared with CRT. 2015 Elsevier Inc. All rights reserved.Introduction
The treatment paradigm in cancer care is “individualized”
treatment, tailoring the treatment to the specific features of
the patient and the tumor. The challenge is how to integrate
clinical,molecular, and imaging information in a quantitative
way to obtain clinical predictions that accurately estimate
patient outcomes (1). In the field of health technology
assessment, this means that for a proper evaluation of long-
term costs and effects of individualized strategies, cost-
effectiveness models need to incorporate patient and tumor
features that may affect treatment decisions, disease pro-
gression, survival, adverse events, and quality of life.
An example of individualized treatment in non-small cell
lung cancer (NSCLC) is the possibility to tailor radiation
therapy treatment to the disease spread of an individual pa-
tient as observed on positron emission tomography (PET)-
CT (2). PET-CT imaging for staging is standard in the
diagnostic workup for NSCLC. However, the technical re-
quirements for using PET-CT in radiation therapy planning
are different from those for diagnosis and staging. An addi-
tional PET-CT scan in treatment planning allows for selective
lymph node irradiation. In addition, on the basis of this PET-
CT scan isotoxic therapy can be administrated, whereby
doses of radiation therapy are individualized according to the
constraints of the organs at risk. Individualizing therapy
through isotoxic treatment planning improves tumor
coverage, decreases the isolated nodal failure rate, and re-
duces the volume of healthy tissues irradiated compared with
CT alone (3, 4). It is therefore justified to order a dedicated
PET-CT scan for radiation therapy purposes, according to
stringent technical specifications.
Further optimization of treatment can be obtained by
hyperfractionated and accelerated radiation schemes,
whereby patients receive lower-dose grays per fraction
(hyperfractionated) twice daily, in a shorter overall treat-
ment time (accelerated) (5). The 8-hour treatment interval
between doses allows the healthy tissue to recover, thereby
decreasing toxicity. Accelerated schemes have shown small
reductions in mortality (5) and were shown to be more
effective but also more costly than conventional radiation
therapy (6).PET-based treatment planning for selective lymph node
irradiation is the preferred treatment strategy for patients
eligible for radiation therapy according to the European
guidelines (7). It is generally believed that treatment pat-
terns vary over hospitals and regions, owing to differences
in guidelines implementation (8). Specifically, it is not clear
to what extent advanced imaging and modified radiation
therapy schemes are implemented in standard care.
Because new technologies in personalized care are often
expensive, hospitals may be apprehensive to implement
these technologies as standard care.
In this study we evaluated the long-term health effects,
costs, and the cost-effectiveness of PET-CTebased isotoxic
accelerated radiation therapy treatment (PET-ART)
compared with conventional CT-based radiation therapy
treatment (CRT) in NSCLC patients, using a previously
developed and validated micro-simulation model (9).Methods and Materials
Model description
The micro-simulation model used in this analysis simulates
the disease progression and death of individual lung cancer
patients until they are deceased or have reached a pre-
specified time-horizon of 3 years. Figure 1 presents the
structure of the model, consisting of 4 health states. All
patients start in state “Alive,” where they are assumed to
receive radiation therapy treatment. Over time, they can
develop a local recurrence (“LR” [transition 1]), a distant
metastasis (“DM” [transition 2]), or they can die without
the detection of an LR or DM (“Death” [transition 3]).
After they move to LR or DM, they are again at risk for
Death (transitions 4 and 5, respectively). In addition to the
4 health states, the model keeps track of the occurrence of
the adverse events “Dyspnea” and “Dysphagia.”
Individual patients were simulated by repeatedly sam-
pling a patient profile consisting of patient and tumor
characteristics (World Health Organization [WHO] per-
formance status, gross tumor volume, and number of lymph
nodes affected) that are randomly drawn from prespecified
λ2(t, WHO, Nstage, RT2, CHT, GTV)























WHO ps =WHO performance status, Nstage = number of lymph nodes affected, RT2= PET-ART (RT2=1) versus CRT (RT2=0), CHT= chemotherapy, GTV=gross tumour volume, LR=local
recurrence, DM=distant metastasis.
Fig. 1. Model structure of the micro-simulation model. From the health state “Alive” patients can develop Dysphagia or
Dyspnea during or shortly after radiation therapy treatment.
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profile is drawn, the disease progression after radiation
therapy treatment is simulated for that individual. Transi-
tion rates between health states and the probability of
acquiring toxicity depend on the patient profile and the type
of treatment planning.
The micro-simulation model is programmed in Excel
2003 (Microsoft, Redmond, WA) and Visual Basic Editor
2003 (Microsoft, Redmond, WA).Data used for model quantification and radiation
therapy treatment strategies
Data on patient and tumor characteristics, toxicity, and
follow-up were available for 200 NSCLC patients with
inoperable stage I-IIIB receiving curative sequential che-
moradiation or radiation therapy alone. The Maastro Clinic
collected data on patients who were referred to their hos-
pital between 2002 and 2009, according to a treatment
protocol that described treatment regimen and data
collection (10-12).
In detail, both radiation therapy treatment strategies
are as follows. With CRT, patients received a radiation
dose of either 70 Gy (stage I-II) or 60 Gy (stage III), in
daily 2-Gy fractions in a mean overall treatment time of
42 days. With PET-ART, patients received a radiation
dose of 54.0-79.2 Gy, delivered in 1.8-Gy fractions, twice
daily, depending on the mean lung dose or spinal cord
dose constraint. The mean overall treatment time was
25 days.
All patients received a diagnostic PET scan at baseline.
Patients who received PET-ART received an additionalPET-CT scan for treatment planning in the treatment po-
sition. Baseline characteristics are presented in Table E1
(available online at www.redjournal.com).
Parameters of the disease model
The distribution of baseline clinical features and tumor fea-
tures, used to draw a hypothetical patient in the model,
correspond to the distribution of these features in the general
NSCLC population. Although the cohort of patients was
separately drawn for both treatment strategies, baseline
characteristics were similarly distributed to eliminate the
bias due to different baseline characteristics (Table E2,
available online at www.redjournal.com). The transitioning
of patients between health states is governed by personalized
hazard rates. These hazard rates consist of a baseline time-
dependent hazard that is the same for each individual, and
a personal time-independent hazard rate ratio (HR) that
varies according to the features of the patient and the tumor
and the treatment given. Parameter values are given in
Table 1. Estimation of the model parameters has been
described elaborately in the Supplementary Material (avail-
able online at www.redjournal.com). Model predictions for
each transition of the model, for overall survival, and for
toxicity were internally and externally validated (9).
Costs and health-related quality of life
A hospital perspective was taken in this study. Resource use
estimates were based on the data of the Maastro Clinic and
the literature (13-15). Costs were based on the Dutch
Manual for Costing in Economic Evaluations, the Dutch
Table 1 List of input parameters for health effects, resource use, and unit costs
Parameter
Point estimate
(HR, OR, probability) SE (a, b) Distribution
Reference
(year)
Multistate model (HRs) Lognormal 9, 10
Transition 1
WHO PS 2.34 0.50
N stage 0.75 0.43
RT2 0.47 0.41
Chemotherapy 2.37 0.00
GTV (per 10 cm3) 1.01 0.47
Transition 2
WHO PS 2.31 0.32
N stage 1.51 0.27
RT2 0.10 0.37
Chemotherapy 3.21 0.00
GTV (per 10 cm3) 1.02 0.34
Transition 3
WHO PS 1.72 0.45
N stage 2.98 0.35
RT2 0.40 0.33
Chemotherapy 0.60 0.00






Dysphagia (ORs) Normal 9, 10
RT2 0.80 0.23
N stage 1.27 0.23
Intercept for dysphagia Z 2 2.06 0.24
Intercept for dysphagia 3 4.18 0.32
Dyspnea (probabilities) Dirichlet* 9, 10
CRT grade <2 0.63 (12; 7)
CRT grade 2 0.32 (6; 1)
CRT grade 3 0.05 y
PET-ART grade <2 0.74 (148; 52) Dirichlet* 9, 10
PET-ART grade 2 0.16 (32; 20)
PET-ART grade 3 0.10 y
Probability of irreversible dyspnea 0.71 (5; 2) Gamma 27
Resource use
Radiation therapy
No. of fractions CRT 31 1.89 Normal 10
No. of fractions PET-ART 36 5.71 Normal
Adverse events
Days of medication with dysphagia 30 Fixed 19
Days of hospital admission with dysphagia 2 (13.33; 0.15) Gamma 15
Days of tube feeding with dysphagia 22 (220.50; 0.10) Gamma 15
Days of irreversible dyspnea Lifelong
Outpatient visits





Radiation therapy per fraction 244 16.95 Lognormal 14 (2010)
PET-scan 1325 Fixed 18 (2012)
Outpatient visits 60 Fixed 17 (2010)
(continued on next page)
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Table 1 (continued )
Parameter
Point estimate
(HR, OR, probability) SE (a, b) Distribution
Reference
(year)
Total costs in state LR and DM per year
(mean, median)
33,220, 22,992 13 (2005)
Daily costs used for base-case scenario (mean) 91
Breakdown of total costs in state LR and DM (median)
Hospitalization 12,428 16,808 Lognormal
Outpatient visits 2168 3753 Lognormal
Chemotherapy 5016 963 Lognormal
Diagnostic tests 245 723 Lognormal
Lab 3135 3070 Lognormal
End-of-life care costs in cancer per year
(palliative care only)
6603 737 Lognormal 16 (2000)
Toxicity
Medication dysphagia per day 2.80 Fixed 19 (2012)
Treatment irreversible dyspnea per year 1140 112 Gamma 14 (2000)
Hospital admission per day 462 Fixed 17 (2010)
Replacing/removing tube 105 Fixed 17 (2009)
Tube feeding per day 25 Fixed 15 (2009)
Utilities
No progression (reference value)z 0.825 0.067 Beta 20
Disutility any adverse event 0.353 0.05 Beta 15
Disutility local recurrence 0.053 0.034 Beta 20
Disutility metastatic disease 0.252 0.032 Beta 20
Abbreviations: CHT Z chemotherapy; CRT Z conventional CT-based radiation therapy treatment; DM Z distant metastasis; GTV Z gross tumor
volume; HR Z hazard ratio; LR Z local recurrence; N stage Z number of lymph nodes affected; OR Z odds ratio; PET-ART Z positron emission
therapyebased isotoxic accelerated radiation therapy treatment; RT2 Z effect of PET-ART versus CRT; WHO PS Z World Health Organization
performance status.
* Dirichlet distributions were based on a series of conditional b distribution for probabilities of dyspnea grade <2 (p1) and dyspnea grade 2 (p2).
y The probability of dyspnea grade 3 was estimated by 1-p1-p2.
z “No progression” is the reference utility. Utilities for the states LR and DM are obtained by subtracting corresponding disutility.
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and the literature (16-19). All costs were reported in euros.
Price indices were used to convert costs to the 2012 price
level.
Each health state in the model is associated with a
specific utility, reflecting the quality of life in that health
state. The utility estimates for the model are obtained from
a meta-analysis of 23 studies of utilities in NSCLC patients
(20) and from a cost-effectiveness study (15).
Resource use estimates, costs, and utility values are
presented in Table 1. The Supplementary Material (avail-
able online at www.redjournal.com) describes cost calcu-
lations and utility values in more detail.Base-case analysis
In the base-case analysis, model predictions for both radi-
ation therapy strategies were obtained by simulating the
health trajectories of a cohort of 50,000 patients from the
moment they start radiation therapy until they die or have
reached the time-horizon of 3 years. This time horizon was
chosen because it was deemed appropriate to cover the
health benefits and costs of radiation therapy in NSCLC.Additionally, in the base-case analysis the following
assumptions were made. (1) The type of radiation therapy
treatment strategy affects all transitions, and this effect is
different for each transition; (2) Patients in both treatment
groups have similar resource use after the end of radiation
therapy treatment, until their transitioning to the next event;
(3) The risk to develop a DM after an LR is implicitly
incorporated in the risk of death after LR; (4) Patients with
an LR and patients with a DM have similar costs per unit of
time, independent of their history; and (5) All deaths within
the time horizon are caused by cancer.
For both radiation therapy strategies, we determined the
proportion of patients experiencing LR or DM, the pro-
portion of deaths, the proportion and grade of both adverse
events, the average total costs, the average life-years lived
(LYs), and the average quality-adjusted life-years
(QALYs). To obtain the QALY estimates per patient, we
multiplied the time in a health state by the utility of that
state and subsequently summed over all health states that
are visited until death. Costs and LYs were discounted at
3%. We computed the incremental cost-effectiveness ratio
(ICER) of PET-ART compared with CRT by dividing the
difference in costs by the difference in LYs. The incre-
mental cost utility ratio (ICUR) of PET-ART compared
Bongers et al. International Journal of Radiation Oncology  Biology  Physics862with CRT was obtained by dividing the difference in costs
by the difference in QALYs.
Uncertainty analysis
For the probabilistic analysis, we assigned distributions to
all the model input parameters (Table 1). We randomly
created 1000 parameter sets, and for each set of parameters,
50,000 patients were simulated. Model predictions for the
difference in costs and LYs between PET-ART and CRT,
and for the difference in costs and QALYs were represented
on a cost-effectiveness plane.
For the HRs that were used to calculate the profile-
specific transition rates between the health states in the
model, normal distributions were assumed. By means of
Cholesky decomposition of the covariance matrix, corre-
lated draws for all the HRs were obtained (21). The same
was done to obtain correlated random draws for the pa-
rameters of the regression model for dysphagia. The
probabilities of dyspnea grade 2 and grade 3 or higher were
varied according to Dirichlet distributions (21).
To draw conclusions regarding cost-effectiveness of
PET-ART compared with CRT, a cost-effectiveness
acceptability curve was obtained, which presents the
probability that PET-ART is cost-effective compared with
CRT according to the simulation results for the 1000
parameter sets, for different threshold values for 1 unit in
health gain. According to the WHO, a strategy is consid-
ered highly cost-effective if the ICUR does not exceed the
value of once the gross domestic product (GDP) per capita
purchasing power parity of a country (22). This means a
threshold value of V25,982 per QALY in Europe and
V31,594 in the United States, which has the highest GDP
worldwide (23). To explicitly explore the sensitivity of the
ICER and ICUR of PET-ART versus CRT to the modelTable 2 Base-case scenario: Model predictions for CRT and PET-A
Parameter
No discounting Discounted a
CRT PET-ART CRT PE
Proportion LR 0.14
Proportion M 0.49









Total LYs 1.39 1.82 1.38*
Total QALYs 1.07 1.40 1.04*
Total costs (V) 25,186 25,720 24,879* 25,
Abbreviations: CI Z confidence interval; ICER Z incremental cost-effecti
M Z metastasis; QALYs Z quality-adjusted life years. Other abbreviations a
* Numbers are rounded.assumptions, we carried out scenario analyses for health
effects, costs, and utilities (see Supplementary Material,
available online at www.redjournal.com).Results
Table 2 shows the results of the base-case analysis. For
PET-ART, the proportions of LR, DM, and death after three
years were smaller than for CRT. However, proportions of
severe toxicity were smaller for CRT. Incremental life years
and incremental QALYs were 0.42 and 0.33 in favor of
PET-ART. PET-ART was slightly more expensive; incre-
mental costs of PET-ART compared with CRT were V569.
The incremental costs and effects resulted in an ICER of
V1360/LY and an ICUR of V1744/QALY. The model
predictions of the base-case analysis for progression-free
and overall survival are presented in Supplementary
Figure 1 (available online at www.redjournal.com).
Uncertainty analyses
Figure 2A and B show the results of the probabilistic
sensitivity analysis for LYs gained and QALYs gained in 2
cost-effectiveness planes. The grey dots correspond to the
1000 parameter sets, each parameter set representing the
simulated results of 50,000 patients. The black dot and the
black horizontal and vertical lines in each plane correspond
with the point estimates and their 95% confidence intervals
(CIs) for the difference in LYs, QALYs, and costs as shown
in Table 2.
Of 1000 ICER and ICUR replicates, 36% of the repli-
cates are in the lower right quadrant, indicating that PET-
ART both improves outcomes and reduces costs. The
remaining 64% is located in the upper right quadrant,RT over a 3-year time horizon (nZ50,000)

















1.79* 0.42 0.19, 0.61
1.38* 0.33 0.13, 0.49
449* 569 5327, 6936 1360 1744
veness ratio; ICUR Z incremental cost-utility ratio; LYs Z life years;
s in Table 1.
Costs and LYs for PET-ART vs CRT
(n = 50000 per set)
Costs and QALYs for PET-ART vs CRT
(n = 50000 per set)
1000 parameter sets base case scenario LYs 95% CI
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Fig. 2. Results of the probabilistic sensitivity analysis showing incremental costs and incremental life years (LYs) (A) and
quality-adjusted life-years (QALYs) (B) for positron emission tomographyebased isotoxic accelerated radiation therapy
treatment (PET-ART) compared with conventional CT-based radiation therapy treatment (CRT).
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costs compared with CRT. The cost-effectiveness accept-
ability curve (Fig. 3) shows that at a threshold value of
V18,000 per QALY, there is a 95% probability that PET-
ART is cost-effective. Considering the aforementioned
WHO-based threshold value of V25,982 per QALY, the
probability that PET-ART is cost-effective compared with
CRT is 99%.
None of the scenario analyses resulted in an ICER or
ICUR higher than the aforementioned WHO-based
threshold values, which would have affected the treatment
decision.Discussion
In this study we showed that, given the available data,
individualized PET-ART for NSCLC seems to be cost-
effective compared with CRT. In our base-case analysis we
found that patients receiving PET-ART have an average of
0.42 (95% CI 0.19-0.61) incremental LYs and 0.33 (95% CI
0.13-0.49) incremental QALYs over similar patients
receiving CRT. One year of survival gain costs V1360, and
a gain of 1 year in quality-adjusted survival costs V1744. Inour probabilistic analysis, PET-ART was more effective
than CRT in all simulations. The probability that PET-ART
is not only more effective but also less costly than CRTwas
36%.
In the present study we compared a more individualized
strategy, PET-ART, with a less personalized treatment
strategy, CRT. The PET-CTebased strategy is a way to
improve the detection of lymph nodes affected with tumor
activity and to individualize the dose of radiation therapy
according to the constraints of the organs at risk (24). A
wide variability of doses is the consequence. In addition, a
modified accelerated scheme was used. The conventional
radiation therapy treatment strategy refers to CT planning
for affected lymph nodes based on anatomical visualiza-
tion, and consequently a fixed dose is optimized according
to the anatomy of the tumor and the organs at risk.
Ideally we would have included a number of other
strategies in our evaluation, such as a purely hypothetical
nonindividualized PET-CTebased planning strategy and an
individualized CT-based planning strategy, with and
without an accelerated radiation therapy scheme. However,
no data for such alternative strategies were available.
A recent meta-analysis evaluated modified radiation
therapy schemes, concluding that accelerated radiation
Cost-effectiveness acceptability curve






















Fig. 3. Cost-effectiveness acceptability curve for quality-adjusted life-years (QALYs) and life years (LYs): The probability
that positron emission tomographyebased isotoxic accelerated radiation therapy treatment is cost-effective compared with
conventional CT-based radiation therapy treatment for different threshold values.
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meta-analysis were used in a cost-effectiveness study,
showing increased effects and costs for all schemes other
than conventional radiation therapy (6). The radiation
therapy scheme evaluated in the present study was not only
accelerated but isotoxic as well. This scheme is believed to
be beneficial in terms of tumor coverage, the isolated nodal
failure rate, and the volume of healthy tissues irradiated (3,
4). However, long-term effects on overall survival,
progression-free survival, quality of life, and costs were
never evaluated. Our results indicate that PET-ART also
leads to better progression-free survival, overall survival,
and quality of life.
Our study has a number of limitations. First, we were
restricted to estimate the effect in patients who were treated
with radiation therapy alone (with or without sequential
chemotherapy) rather than concurrent chemoradiation
therapy. It is important to note that at present, concurrent
chemoradiation therapy remains the standard treatment
option for stage III patients. However, this may change in
the future as radiation therapy schemes are further opti-
mized, because concurrent chemoradiation therapy is
associated with a considerable patient burden. Indeed,
because the improved survival of concurrent chemo-
radiation therapy over sequential chemoradiation therapy is
due to improved local tumor control with a similar hazard
for distant metastases (25), it may be hypothesized that
optimized sequential chemoradiation therapy alone may
lead to the same survival but with fewer side effects. In
addition, the guideline recommendation for concurrent
chemoradiation therapy is based on the results of a meta-
analysis that included trials in which relatively fit patients
with minimal comorbidities were included (25). These
patients are not representative of the typical NSCLC patient
population (7). Indeed, for many patients, sequential che-
moradiation therapy or radiation therapy alone isconsidered the best treatment option. In case of stage I
patients who are ineligible for surgery, stereotactic radia-
tion therapy is currently standard treatment. A small pro-
portion of the patients in our data had stage I disease (15%).
However, these patients were not eligible for stereotactic
treatment, nor for concurrent chemoradiation therapy,
owing to their tumor location. They received sequential
therapy instead. Because the patients in our data were not
treated in a trial setting, but to their best treatment option
available at the time, we believe that our results are
representative and relevant for a real-life clinical setting.
Second, we used a time-horizon of 3 years instead of a
lifelong time horizon. However, because in the data more
than 80% of lung cancer deaths had already occurred within
3 years, this time-horizon seems appropriate for this patient
group. Moreover, because only few events occurred after
3 years, the timing of events cannot be accurately predicted
after 3 years.
Finally, our study was carried out in a Dutch health
setting, using mainly Dutch sources for costs and resource
use. However, although costs vary widely over countries,
the results of the scenario analyses showed that varying cost
and resource did not affect our main conclusion.
Evaluations of long-term health effects of novel radia-
tion therapy strategies in randomized, controlled trials are
scarce (26). To extrapolate short-term evidence to long-
term predictions, we carried out a model-based evalua-
tion. We have used the best available evidence to estimate
all parameters of the model and validated the model both
internally and externally. By using this micro-simulation
model, we were able to assess the consequences of uncer-
tainty in all health parameters of the model on model
predictions, taking the correlations among input parameters
into account. Patient heterogeneity is included in the model.
As such, we were able to simulate a randomized, controlled
trial, thereby eliminating bias due to differences in baseline
Volume 91  Number 4  2015 Economic evaluation of radiation therapy 865characteristics between the 2 treatment groups (9). We
explicitly opted for a micro-simulation model to easily
adjust the patient population for other decision problems in
radiation therapy treatment for lung cancer. With these
properties, the micro-simulation model provides a proxy for
empirical evidence, while clearly presenting the uncertainty
of the model and allowing for evaluations of other relevant
scenarios. This model will be used to evaluate new de-
velopments in radiation therapy treatment, with both
treatment strategies in the present study as reference
strategies.
Conclusion
According to the available data, we found that PET-ART
is likely to be more effective than CRT and seems to be
cost-effective as well. There is a 64% probability that
PET-ART is more costly, but the additional cost is limited.
These findings can support decision makers to implement
PET-ART schemes in radiation therapy treatment
planning.
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